



**Claudio Gobbi**

**Contact**

Claudio Gobbi

## Publications (21)

Sparasci D, Schilg-Hafer L, Schreiner B, Scheidegger O, Peyer A, Lascano A, Vicino A, Décard B, Tsouni P, Humm A, Pianezzi E, Zezza G, Hundsberger T, Dietmann A, Jung H, Kuntzer T, Wilder-Smith E, Martinetti-Lucchini G, Petrini O, Fontana S, Gowland P, Niederhauser C, Gobbi C, Ripellino P. Immune triggers preceding neuralgic amyotrophy. *Eur J Neurol* 2024; 31:e16462.

Greselin M, Lu P, Melie-Garcia L, Ocampo-Pineda M, Galbusera R, Cagol A, Weigel M, de Oliveira Siebenborn N, Ruberte E, Benkert P, Müller S, Finkener S, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Diepers M, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Gobbi C, Leppert D, Kim O, Cattin P, Hoepner R, Roth P, Kappos L, Kuhle J, Granziera C. Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort. *Bioengineering (Basel)* 2024; 11

Cagol A, Benkert P, Melie-Garcia L, Schaedelin S, Leber S, Tsagkas C, Barakovic M, Galbusera R, Lu P, Weigel M, Ruberte E, Radue E, Yaldizli O, Oechtering J, Lorscheider J, D'Souza M, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Remonda L, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Cattin P, Absinta M, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. *Neurology* 2023; 102:e207768.

Abdelhak A, Benkert P, Schaedelin S, Boscardin W, Cordano C, Oechtering J, Ananth K, Granziera C, Melie-Garcia L, Montes S, Beaudry-Richard A, Achtnichts L, Oertel F, Lalive P, Leppert D, Müller S, Henry R, Pot C, Matthias A, Salmen A, Oksenberg J, Giulio D, Zecca C, D'Souza M, Du Pasquier R, Bridel C, Gobbi C, Kappos L, Hauser S, Cree B, Kuhle J, Green A, UCSF, MS EPIC, and the SMSC Study Teams. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. *JAMA Neurol* 2023

Ripellino P, Lascano A, Scheidegger O, Schilg-Hafer L, Schreiner B, Tsouni P, Vicino A, Peyer A, Humm A, Décard B, Pianezzi E, Zezza G, Sparasci D, Hundsberger T, Dietmann A, Jung H, Kuntzer T, Wilder-Smith E, Martinetti-Lucchini G, Petrini O, Fontana S, Gowland P, Niederhauser C, Gobbi C. Neuropathies related to hepatitis E virus infection: A prospective, matched case-control study. *Eur J Neurol* 2023; 31:e16030.

Meier S, Willems E, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C, Abdelhak A, Thebault S, Achtnichts L, Lalive P, Müller S, Pot C, Salmen A, Giulio D, Zecca C, D'Souza M, Orleth A, Khalil M, Buchmann A, Du Pasquier R, Yaldizli O, Derfuss T, Berger K, Hermesdorf M, Wiendl H, Piehl F, Battaglini M, Fischer U, Kappos L, Gobbi C, Granziera C, Bridel C, Leppert D, Maceski A, Benkert P, Kuhle J. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. *JAMA Neurol* 2023; 80:287-297.

Todea A, Melie-Garcia L, Barakovic M, Cagol A, Rahmanzadeh R, Galbusera R, Lu P, Weigel M, Ruberte E, Radue E, Schaedelin S, Benkert P, Oezguer Y, Sinnecker T, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Lalive P, Bridel C, Zecca C, Derfuss T, Remonda L, Wagner F, Vargas M, Du Pasquier R, Pravatà E, Weber J, Gobbi C, Leppert D, Wuerfel J, Kober T, Marechal B, Corredor-Jerez R, Psychogios M, Lieb J, Kappos L, Cuadra M, Kuhle J, Granziera C. A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. *J Magn Reson Imaging* 2023

Achtnichts L, Zecca C, Findling O, Kamm C, Müller S, Kuhle J, Lutterotti A, Gobbi C, Viviani C, Villiger-Borter E, Nedeltchev K. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS). *BMJ Neurol Open* 2023; 5:e000304.

Friedli C, Salmen A, Achtnichts L, Derfuss T, Gobbi C, Kuhle J, Lalive P, Müller S, Papadopoulou A, Pot C, Zecca C, Chan A, Kamm C. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022. *Clinical and Translational Neuroscience* 2022

Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea R, Rahmzadeh R, Galbusera R, Lu P, Weigel M, Melie-Garcia L, Ruberte E, Siebenborn N, Battaglini M, Radue E, Yaldizli O, Oechtering J, Sinnecker T, Lorscheider J, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Remonda L, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Cattin P, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. *JAMA Neurol* 2022; 79:682–692.

Oechtering J, Lincke T, Schaedelin S, Décard B, Maceski A, Orleth A, Meier S, Willemse E, Buchmann A, Khalil M, Derfuss T, Benkert P, Heijnen I, Regeniter A, Müller S, Achtnichts L, Lalive P, Salmen A, Pot C, Gobbi C, Kappos L, Granziera C, Leppert D, Schlaeger R, Lieb J, Kuhle J, Swiss MS Cohort Study. Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. *Ann Neurol* 2022; 91:814–820.

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive P, Mueller C, Müller S, Naegelin Y, Oksenberg J, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani M, Granziera C, Piehl F, Leppert D, Kuhle J. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. *Lancet Neurol* 2022; 21:246–257.

Oechtering J, Naegelin Y, Maceski A, Meier S, Berger K, Wiendl H, Lincke T, Lieb J, Yaldizli O, Sinnecker T, Derfuss T, Regeniter A, Zecca C, Gobbi C, Kappos L, Granziera C, Leppert D, Kuhle J, Conen D, Aeschbacher S, Subramaniam S, Schaedelin S, Benkert P, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Fischer-Barnicol B, Orleth A, Chan A, Pot C, Barakovic M, Rahmzadeh R, Galbusera R, Heijnen I, Lalive P, Wuerfel J, Swiss Multiple Sclerosis Cohort Study. Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. *Ann Neurol* 2021; 90:477–489.

Gantenbein A, Agosti R, Gobbi C, Flügel D, Schankin C, Viceic D, Zecca C, Pohl H. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study. *Cephalalgia* 2021; 41:1181–1186.

Rodgers S, Calabrese P, Ajdacic-Gross V, Steinemann N, Kaufmann M, Salmen A, Manjaly Z, Kesselring J, Kamm C, Kuhle J, Chan A, Gobbi C, Zecca C, Müller S, von Wyl V. Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. *J Psychosom Res* 2021; 144:110402.

Kaufmann M, Puhan M, Salmen A, Kamm C, Manjaly Z, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR). 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. *Front Neurol* 2020; 11:156.

Achtnichts L, Salmen A, Chan A, Czaplinski A, Derfuss T, Du Pasquier R, Findling O, Gobbi C, Zecca C, Müller S, Kamm C, Kuhle J, Lalive P, Martin R, Pot C, Papadopoulou A. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. *Clinical and Translational Neuroscience* 2019

Barin L, Kamm C, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan M, von Wyl V, Swiss Multiple Sclerosis Registry. How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. *Mult Scler* 2019; 26:489–500.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J, Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. *Ann Neurol* 2017; 81:857–870.

Giulio D, Kamm C, Mattle H, Lotter C, Du Pasquier R, Schlupe M, Pot C, Lalive P, Yaldizli O, Gobbi C, Kappos L, Kuhle J, Louvion J, Derfuss T, Stippich C, Benkert P, Lorscheider J, Müller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue E, Sprenger T, SMSC Scientific Board. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. *PLoS one* 2016; 11:e0152347.

Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Bortler E, Traber M. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. *Eur Neurol* 2013; 70:35-41.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)